Semaglutide

BACKGROUND: Body contouring surgery (BCS) addresses excess skin following significant weight loss. While bariatric surgery has been the primary intervention for massive weight loss, the rise of GLP-1 receptor agonists (GLP-1 RAs) introduces a new pat…

PURPOSE OF REVIEW: This article reviews the evidence for cardiovascular and renal risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM), based on randomized controlled trials, including emerging…

BACKGROUND: Metabolic complications after kidney transplantation (KT) significantly affect graft and patient survival. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer cardio-renal benefits in the general population, but evidence in KT reci…

BACKGROUND: Type 2 diabetes mellitus (T2D) is a rapidly growing global health concern requiring innovative treatment methods. Ozempic (semaglutide), a glucagon-like peptide-1 receptor agonist, has proven consistent effectiveness in lowering blood glu…

Obesity is a chronic, multifactorial condition strongly associated with increased cardiovascular and metabolic risk, as well as the development of systemic complications. Recent evidence from randomized controlled trials-including SELECT, STEP-HFpEF,…

AIM: A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. METHODS: Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide b…

Obesity management is challenged by high rates of recurrent weight gain following initial loss. We systematically reviewed 29 randomized controlled trials comparing long-term outcomes of lifestyle interventions, semaglutide, and metabolic and bariatr…

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation over…

Long-term high-fat diets (HFD) induce obesity, neuroinflammation, and cognitive decline, increasing Alzheimer's disease (AD) risk. This study explores whether Semaglutide, a GLP-1 receptor agonist, mitigates these effects by modulating microglia via…

PURPOSE: An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists. We performed a pharmaco…

BACKGROUND AND AIMS: Polycystic ovary syndrome (PCOS) and obesity increase the risk of infertility, preterm birth and birth of a hypertrophic neonate. Effective weight loss can improve this disorder. The aim of this study was to evaluate the effect o…

GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have bee…

AIMS/HYPOTHESIS: Type 2 diabetes is associated with worsened stroke outcome and lasting disability. The underlying mechanisms are undetermined, and no therapy is available. We experimentally investigated whether pharmacologically targeting obesity, w…

The emergence of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has transformed the landscape of weight management and diabetes treatment. Initially developed for type 2 diabetes mellitus, these medications have gained widespread popul…

OBJECTIVE: This study examined racial differences in weight loss and clinical response to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity using real-world data. METHODS: We retrospectively analyzed our institution…

OBJECTIVE: Semaglutide shows potential in cardiovascular protection, yet its specific role and mechanism in H/R injury are unclear. Given the role of autophagy in cardiomyocyte protection and the unclear mechanism of semaglutide in H/R - induced inju…